FDA Approves GSK’s Hibsago for Chronic Hepatitis B Treatment
GSK announced that the FDA approved Hibsago (bepirovirsen) for chronic hepatitis B treatment in the U.S.
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) partner GSK today announced that the U.S. Food and Drug Administration (FDA) has approved Hibsago (bepirovirsen) for the treatment of chronic hepatitis B (CHB) virus infection in combination with nucleos(t)ide analogue reverse transcriptase inhibitor (NrtI…